Phil Lake to head Theorem biopharmaceutical franchise in respiratory

Has remit to build respiratory business of American firm globally

Theorem Clinical Research has promoted Phil Lake to head its biopharmaceutical franchise in respiratory. As Executive Director of Biopharmaceutical Development, Respiratory, Lake will be responsible for oversight on major projects as well as building Theorem’s respiratory business globally.

Prior to joining Theorem as Senior Director of Project Management in 2012, Lake held positions of Managing Director of Springfield Clinical Consulting; Executive Director of Project Management in Europe for Covance; and Senior Clinical Research Manager for GlaxoSmithKline in London, UK. He has significant therapeutic experience in respiratory disorders, including numerous COPD and asthma studies.

You may also like

Research & Development

Chiltern to purchase Theorem Clinical Research

To expand its global reach and scientific expertise
Research & Development

Theorem opens clinical supplies facility in Frankfurt, Germany

The expansion will offer both ambient and refrigerated storage space
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Manufacturing

Servier opens new €86m biologics production facility in Loiret, France

The company's Bio-S facility will be responsible for the production of biological medicines stemming from its R&D pipeline for preclinical and clinical studies
Manufacturing

Leybold launches Duradry vacuum pump for harsh processes

Advanced technology designed for reliability and efficiency
Subscribe now